KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Capital Leases (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has disclosed Capital Leases for 16 consecutive years, with $720.0 million as the latest value for Q4 2025.

  • For Q4 2025, Capital Leases changed 0.0% year-over-year to $720.0 million; the TTM value through Dec 2025 reached $720.0 million, changed 0.0%, while the annual FY2025 figure was $720.0 million, 0.0% changed from the prior year.
  • Capital Leases hit $720.0 million in Q4 2025 for Regeneron Pharmaceuticals, roughly flat from $720.0 million in the prior quarter.
  • Across five years, Capital Leases topped out at $720.0 million in Q1 2022 and bottomed at $720.0 million in Q1 2022.
  • Average Capital Leases over 4 years is $720.0 million, with a median of $720.0 million recorded in 2022.
  • On a YoY basis, Capital Leases climbed as much as 0.0% in 2023 and fell as far as 0.0% in 2023.
  • Regeneron Pharmaceuticals' Capital Leases stood at $720.0 million in 2022, then changed by 0.0% to $720.0 million in 2023, then changed by 0.0% to $720.0 million in 2024, then changed by 0.0% to $720.0 million in 2025.
  • According to Business Quant data, Capital Leases over the past three periods came in at $720.0 million, $720.0 million, and $720.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.